Browse Articles

Filter By:

  • mRNA vaccines have proven safe and effective in preventing serious illness and death during the COVID-19 pandemic. In this Comment, Morris and Kopetz argue that these technologies offer a novel approach towards personalizing immune-based treatments for patients with cancer with the potential for immune activation beyond commonly utilized immunotherapies.

    • Van K. Morris
    • Scott Kopetz
    Comment
  • This Review discusses mechanisms by which tumour ecosystems adapt to therapeutic stresses and how these could be exploited, as well as challenges associated with tumour heterogeneity. It provides an integrative framework to identify and target vulnerabilities that arise from adaptive responses to overcome cancer therapy resistance.

    • Marilyne Labrie
    • Joan S. Brugge
    • Ioannis K. Zervantonakis
    Review Article
  • The African Esophageal Cancer Consortium is a self-organized consortium of more than 80 physicians and scientists working in eastern and southern African countries. This Comment highlights the role that international collaborations with regional partners at their centre play in expanding local capacities for research and care to address cancer disparities.

    • Christian C. Abnet
    • Geoffrey C. Buckle
    • Russell E. White
    Comment
  • This Review discusses how senescence can be induced in cancer cells and how distinctive features of senescent cancer cells might be exploited for their selective eradication as a potential cancer therapy.

    • Liqin Wang
    • Lina Lankhorst
    • René Bernards
    Review Article
  • In this Journal Club, S. K. Singh and R. Singh discuss a study that used bioreactive, tumour microenvironment-modulating nanoparticles with doxorubicin to treat breast tumour xenograft-bearing mice, leading to reversal of immunosuppression and tumour shrinkage.

    • Santosh Kumar Singh
    • Rajesh Singh
    Journal Club
  • This Review examines recent developments in proteogenomics, key findings from the proteogenomic analyses of a wide range of cancers and emerging applications of proteogenomics to translational studies and immuno-oncology, as well as discussing future prospects regarding integration into clinical trials and patient care.

    • D. R. Mani
    • Karsten Krug
    • Steven A. Carr
    Review Article
  • Asrir et al. show that tumour-associated high endothelial venues (TA-HEVs) in tumour-bearing mice are points of entry for lymphocytes, and increasing TA-HEVs frequency and maturation improves immune checkpoint blockade.

    • Ulrike Harjes
    Research Highlight
  • Kerdidani et al. have identified MHC-II-expressing cancer-associated fibroblasts in non-small-cell lung cancers where they appear to promote anti-tumour immunity.

    • Anna Dart
    Research Highlight
  • The advent of CRISPR technologies has enabled programmable nucleic acid editing in mammalian cells. In this Review, Katti et al. outline the enormous progress that has been made in the application of CRISPR tools to the study of cancer and also describe the potential use of CRISPR systems in clinical cancer management including diagnosis and treatment.

    • Alyna Katti
    • Bianca J. Diaz
    • Lukas E. Dow
    Review Article
  • Yang, Zhang, Luan et al. report that a germline variant that increases the risk of Philadelphia chromosome-like acute lymphoblastic leukaemia upregulates GATA3 expression, which changes chromatin accessibility to allow activation of oncogenic pathways.

    • Sarah Seton-Rogers
    Research Highlight
  • Liquid–liquid phase separation (LLPS) has been revealed as a widespread mechanism underlying the spatiotemporal coordination of biological activities in cells. This Perspective discusses how LLPS shapes the biochemical landscape of cancer cells, providing insight into emerging findings of dysregulated LLPS promoting cancer pathology.

    • Sohum Mehta
    • Jin Zhang
    Perspective
  • In this Comment, Deb et al. explore ‘cancer art’ projects that enable new conversations for a broader audience, advocate for policy and disparity issues, and lead to creative innovations for research.

    • Dhruba Deb
    • Stefani Shoreibah
    • Tal Danino
    Comment
  • Somasundara, Moss, Feigman et al. show that γδ natural killer T-like (NKT) cells expand during the late stages of pregnancy in mice because of changes in mammary epithelial cell surface protein expression, which was associated with suppressed mammary oncogenesis induced by BRCA1 loss or MYC-overexpression.

    • Ulrike Harjes
    Research Highlight
  • Xie and Gu discuss a study that reported the development of a CAR T therapy-based multi-antigen targeting strategy for the treatment of glioblastoma (GBM) in mice, overcoming antigen specificity and heterogeneity.

    • Guiqin Xie
    • Xinbin Gu
    Journal Club
  • This Review discusses the mechanisms underlying the immune response to melanomas, as well as the mechanisms of response and resistance of these tumours to immunotherapies. The lessons learned in melanoma may apply to other tumour types.

    • Shelly Kalaora
    • Adi Nagler
    • Yardena Samuels
    Review Article
  • Vincze et al. have provided definitive evidence for the validity of Peto’s paradox by analysing cancer incidence in the largest study of mammal species to date.

    • Anna Dart
    Research Highlight
  • This Review discusses the complex biology of the family of kallikrein-related peptidases and their context-dependent functions in cancer and the tumour microenvironment, as well as their role in tumour immune suppression and resistance to cancer therapy.

    • Srilakshmi Srinivasan
    • Thomas Kryza
    • Judith Clements
    Review Article
  • Reactive oxygen species (ROS) are highly reactive molecules derived from oxygen during cellular metabolism, which regulate various cell phenotypes. In this Review, Cheung and Vousden outline how pathways controlling ROS production and limitation can contribute to tumorigenesis and how the complexities in the responses of both cancer cells and stromal components to ROS might determine the success or failure of ROS modulating therapies.

    • Eric C. Cheung
    • Karen H. Vousden
    Review Article
  • Thandapani et al. examined the role for tRNA biogenesis in T cell acute lymphoblastic leukaemia (T-ALL), and found that T-ALL cells are sensitive to valine tRNA levels, which could be exploited therapeutically by dietary valine restriction.

    • Sarah Seton-Rogers
    Research Highlight